NewsRoom Articles - Page 2 of 239

FridayJun 05, 2026 10:00 am

LA Calls for Infectious Diseases Vigilance During World Cup

This month and in July, the SoFi Stadium in Los Angeles County will host several World Cup matches, and other tournament-related activities will take place within the county. Accordingly, the health department of the county has put health care providers on notice to be alert for infectious diseases during the tournament. SoFi Stadium will host eight World Cup matches, and the global tournament is coinciding with Pride Month. Because of these events, lots of national and international travelers, at least 150,000, are expected to descend on LA County, and that could provide ideal conditions for many infectious diseases to spread. County health officials warn that the massive…

FridayJun 05, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples. The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings. The global alcohol and drug testing devices market is…

ThursdayJun 04, 2026 10:00 am

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress. The findings, published in the Cell Death & Disease journal, offer a possible mechanism that can be targeted in efforts to develop effective treatments against these tumors. Conducted by a team at Karolinska Institutet, the researchers aimed to investigate what role microglia played in tumor progression and how these cells are impacted by the cancer. In their study, the team found that when microglia are exposed to diffuse midline glioma (DMG) cells, they respond by producing large quantities of fibronectin and…

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The…

WednesdayJun 03, 2026 9:45 am

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment. In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records. Earth Science Tech repurchased 3.7 million shares over the nine months ended December 31, 2025, spending approximately $647,000. Management continues to emphasize shareholder value through balance-sheet management alongside acquisitions and operating growth. The company is scheduled to present to investors at the Planet MicroCap Las Vegas 2026 conference in June. For many investors…

WednesdayJun 03, 2026 9:00 am

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key…

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

TuesdayJun 02, 2026 10:00 am

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

A new viral-based vector that can be inhaled into the lungs could boost the anti-cancer response of the body in patients diagnosed with advanced lung cancer. This new treatment could also restore sensitivity to immune checkpoint inhibitors among patients that had become unresponsive. The new investigational therapy, dubbed KB707, was developed by a team at Cleveland Clinic Cancer Institute. The treatment is based on a vector platform leveraging a modified herpes simplex virus that is non-replicating. The agent delivers cytokines IL-12 and IL-2 directly into the lungs once the patient inhales it. This delivery via inhalation helps to get the therapy into the microenvironment of the tumors in the lungs, and the…

MondayJun 01, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value…

MondayJun 01, 2026 9:00 am

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

LA Calls for Infectious Diseases Vigilance During World Cup

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Earth Science Tech Inc. (ETST) Pairs Healthcare Expansion with Aggressive Share Repurchases

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search